A Professor of Immunopharmacology opinion on our 12/2020 Results

———- Forwarded message ———
מאת: MA Perretti <[email protected]>
Date: יום ד׳, 10 בפבר׳ 2021 ב-19:12‬
Subject: Re: attachments – for QM review
To: Rachel Alkalay

Dear Rachel

Many thanks for sending these files.

I have scanned them, read the Frontier Pharmacol review and also the soft-science article on natural products, or products from plants. Of course digitalis has enabled management of heart insufficiency for decades, and the willow bark contains salicylate, used for centuries to alleviate pain and inflammation (and the chemical base for Aspirin; The William Harvey Research Institute at Queen Mary was founded by Sir John Vane who got the Nobel for his work on the mechanism of action of aspirin).

In essence you have a few experiments demonstrating that your complexes impact on the integrity of subunits of the spike protein of Sars-Cov-2, with subunit 1 and subunit 2 been tested, and complex D probably been the one to take forward. This could be very interesting if the complex reduces cell infection of human cells by the coronavirus. One would expect that co-incubation of virus, complex D and human cells will reduce infection rate at – let’s say. – 48 hours.

At QM in April/May 2020, we invested £50K to set up and run Cat 3 labs and also invested in ad-hoc equipment that could be used for storing COVID patient samples. We are running several projects on COVID, as you may imagine. To me, the next step for the development of your complex, will be to determine if it can impact the infective potential of Sars-Cov-2 on target cells, expressing the Ace2 receptor. Do you agree?

At QM, we run experiments with pseudovirus expressing Sars-Cov-2 Spike protein and can also use the patient virus. So would predict that experiments to assess infectivity and the potential impact of complex D or other products of NCM will be doable.

With respect GLP toxicity I genuinely doubt this. But I can try to trace down Prof Oxford, in fact I am not sure which Institute of the the School he is honorary for.

NDA – I leave Sharon to deal with this.

I will come back with respect to Prof Oxford, in the meantime let me know if and how you wish to progress. If my suggestion above seems interesting to you, I could explore is with the relevant QM colleague.

Best regards

Mauro Perretti PhD FBPhS
Professor of Immunopharmacology
William Harvey Research Institute
Queen Mary University of London

Orcid.ID: 0000-0003-2068-3331

Dean for Research and Research Impact
Barts and The London School of Medicine and Dentistry
Research Deanery Manager – Nasema Uddin BA MA
Email: [email protected]
Tel: +44 (0) 207 8822472


PA – Olivia Carvalho
Email: [email protected]
Tel: +44 (0) 2078828781